Frankfurt - Delayed Quote EUR

Regeneron Pharmaceuticals, Inc. (RGO.F)

515.40

+28.40

+(5.83%)

At close: April 23 at 6:17:44 PM GMT+2

Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.

Zacks 8 hours ago

REGN

CELG-RT
Regeneron to Report Q1 Earnings: What's in Store for the Stock?

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.

Zacks yesterday

REGN
Regeneron Pharmaceuticals (NasdaqGS:REGN) Expands U.S. Capacity With US$3 Billion Fujifilm Partnership

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced a major expansion of its manufacturing capacity, including a $3 billion deal with Fujifilm Diosynth Biotechnologies and further investments at its Tarrytown campus. This expansion underscores Regeneron's commitment to growth within the biopharmaceutical industry and aligns with recent FDA approvals for products like Dupixent. However, the company's share price decreased by 2% over the past week, a move that might have been driven by broader...

Simply Wall St. yesterday

REGN
Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom

President Donald Trump’s tariff policy is the latest blow to a pharmaceutical sector already facing mounting uncertainties, including how Robert F. Kennedy Jr., secretary of Health and Human Services, will change the U.S. healthcare system. While pharmaceuticals have so far been spared from import taxes, Trump has vowed to impose a “major” tariff on the sector “very shortly.” A 25% tariff could reduce earnings in the sector by about 15%, Jefferies analyst Akash Tewari noted last week, but mitigation efforts such as stockpiling, increasing drug prices or shifting manufacturing to the U.S. could reduce the damage to the mid single digits.

Barrons.com yesterday

ABBV

LLY

REGN
Regeneron partners with Fujifilm to broaden manufacturing capacity

Regeneron is currently expanding its Tarrytown campus with an investment of nearly $3.6bn.

Pharmaceutical Technology yesterday

REGN
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

REGN
Drug Companies Step Up 'Make in America' Plans to Counter Tariffs

Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad. Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies. Fujifilm’s plant in Holly Springs, N.C., will make bulk drug material for Regeneron medicines.

The Wall Street Journal yesterday

REGN

RHHBF

RHHBY
Regeneron to invest over $3 billion to boost US manufacturing

Major U.S. drugmakers, including Eli Lilly and Johnson & Johnson, have recently announced additional investments in their U.S. production as they prepare to deal with potential drug import duties from President Donald Trump's administration. Last week, the U.S. opened a national security investigation into pharmaceutical companies to show why the country needs tariffs to boost domestic manufacturing. Under the terms of the deal, Tokyo-based Fujifilm Diosynth's facility in Holly Springs, North Carolina will manufacture and supply drug products for Regeneron's biologic medicines for a span of 10 years.

Reuters yesterday

REGN
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region Regeneron’s ongoing and planned investments in New York and North Carolina infrastructure and manufacturing expected to total more than $7 billion TARRYTOWN, N.Y., April 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a significant expansion of its

GlobeNewswire yesterday

REGN
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2025 Health Care Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 13, 20252025 RBC Capital Markets Global Healthcare Conference at 11:00 a.m. ET on Tuesday, May 20, 2025Bernstein 41st Annual Strategic Decisions Conference at 11:00 a.m. ET on Wednesday, May 28, 2025Goldman Sachs 46th Annual Global Healthcare Conference at 10

GlobeNewswire 2 days ago

REGN
Regeneron's FDA Setback on Eylea HD Dosing 'No Biggie,' Says Oppenheimer

The US Food and Drug Administration's rejection of Regeneron Pharmaceuticals' (REGN) bid to extend t

PREMIUM
MT Newswires 2 days ago

REGN
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Zacks 2 days ago

SNY

REGN
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria

The decision is supported by data from the Phase III Study A and Study C clinical trials.

Pharmaceutical Technology 2 days ago

SNY

REGN
Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD

On April 17, Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD Injection 8 mg. The sBLA seeks approval for EYLEA HD for both the treatment of macular edema following retinal vein occlusion, RVO, and for broadening the dosing schedule to include every 4-week dosing across approved indications. The FDA target action date is August 19, 2025, following the use of a Priorit

TipRanks 4 days ago

REGN
Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment. “Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce the hallmark

TipRanks 4 days ago

SNY

SNYNF

REGN
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for EYLEA HD® (aflibercept) Injection 8 mg across all approved indications. The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its

GlobeNewswire 5 days ago

REGN
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced

GlobeNewswire 5 days ago

SNY

SNYNF

REGN
FDA to review Regeneron’s sBLA for aflibercept injection 8mg

The application is based on data from the Eylea HD clinical programme, including the Phase III QUASAR trial.

Pharmaceutical Technology 6 days ago

REGN
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies Potential for as frequent as monthly dosing for all approved indications would provide greater dosing flexibility for physicians and patients TARRYTOWN, N.Y., April 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the

GlobeNewswire 6 days ago

REGN
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers.

StockStory 8 days ago

EXAS

NTRA

REGN

Performance Overview

Return	RGO.F	S&P 500 (^GSPC)
YTD	-23.75%	-8.60%
1-Year	-38.56%	+6.02%
3-Year	-19.30%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Regeneron Pharmaceuticals, Inc. (RGO.F)

Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

Regeneron to Report Q1 Earnings: What's in Store for the Stock?

Regeneron Pharmaceuticals (NasdaqGS:REGN) Expands U.S. Capacity With US$3 Billion Fujifilm Partnership

Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom

Regeneron partners with Fujifilm to broaden manufacturing capacity

Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs

Regeneron to invest over $3 billion to boost US manufacturing

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines

Regeneron Announces Investor Conference Presentations

Regeneron's FDA Setback on Eylea HD Dosing 'No Biggie,' Says Oppenheimer

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

Sanofi and Regeneron’s dupilumab approved by FDA for urticaria

Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD

Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

FDA to review Regeneron’s sBLA for aflibercept injection 8mg

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

Performance Overview